ENTEROMEDICS INC FILES (8-K) Disclosing Change in Directors or Principal Officers

Edgar Glimpses |

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) On June 23, 2014, the Board of Directors (the "Board") of EnteroMedics Inc. (the "Company") approved a special, one-time cash bonus for all employees of the Company in recognition of the vote by the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee (the "Panel") of the U.S. Food and Drug Administration regarding the safety, efficacy and benefit/risk ratio of the Company's Maestro Rechargeable System that occurred at the Panel's meeting on June 17, 2014.

Each employee, including the officers of the Company, will receive a cash bonus equal to 10\% of such employee's current, annual base salary. The cash bonus shall be pro-rated for any employee who was employed by the Company for fewer than 180 days as of June 17, 2014.

Additionally, as a result of the Panel's positive vote, and after consideration of a peer group compensation study conducted by Pearl Meyer & Partners ("Pearl Meyer") on behalf of the Company, the Board approved increases to the base annual salary of its officers, effective as of July 1, 2014. The Board adopted the salary increases based upon the recommendations of Pearl Meyer in order to align the compensation of the Company's officers with that of their peers in comparable companies. The following table sets forth the increase to the annual base salary for each of the Company's named executive officers and their new annual base salary as of July 1, 2014.

Annual Base Salary as of Name Position Salary Increase July 1, 2014 Mark Knudson Chairman, President, Chief $ 35,500 $ 389,552 Executive Officer Greg Lea Senior Vice President, Chief $ 27,500 $ 322,507 Financial Officer, Chief Operating Officer Adrianus Donders Senior Vice President of Research $ 13,000 $ 276,742 and Advanced Development Katherine Tweden Vice President, Clinical and $ 13,000 $ 277,258 Regulatory


DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Symbol Name Price Change % Volume


Emerging Growth

Relevium Technologies Inc.

Relevium Technologies Inc is engaged in the acquisition of products, technologies and businesses relating to musculoskeletal function, specifically Pain Relief, Injury Recovery and Active Performance.

Private Markets


Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.